Recently, a team of quality and technical experts from Reputable pharmaceutical manufacturers visited Anhui Newman Fine Chemical Co., Ltd. for on-site factory inspection and technical exchanges. Both parties conducted comprehensive verification and discussions covering production control, quality management system, R&D innovation and in-depth supply chain cooperation of medical-grade carbomer, jointly safeguarding the safety of pharmaceutical excipients with stringent standards.

Relevant departments of Newman received the delegation and held special technical meetings, presenting the company’s medical-grade carbomer product portfolio, technological upgrading achievements and standardized quality management system. The audit was carried out in strict accordance with GMP, ChP 2025, USP/NF, EP, BP and other authoritative pharmacopeia standards, evaluating product compliance, core specifications and full-process risk control system.

Adopting dual inspection modes of document review and on-site verification, the expert team systematically checked production qualifications, technical documents, quality specifications, test reports, batch production records, deviation handling and change management files to verify the completeness, standardization and implementation effect of the management system. Inspectors also visited production workshops, clean areas, testing centers and warehouses, focusing on viscosity range, residual impurities, microbial limits, heavy metal control and other key indicators, as well as production traceability and whole-process risk control mechanisms.

As a core polymer excipient for pharmaceutical preparations and high-end oral care products, medical-grade carbomer directly affects drug safety and product efficacy, serving as an essential raw material for pharmaceutical supply chains. With years of dedication to carbomer R&D and manufacturing, Newman has established a complete product lineup including homopolymer, copolymer and interpolymer to meet diverse formulation demands.

1) Carbomer homopolymer: carbomer homopolymer type A such as NM-Carbomer 971P, 71G, 981G.  with 0.5% solution viscosity :4000~11000mPas; And Carbomer Homopolymer Type B such as NM-Carbomer 974P, 934P, with 0.5% solution viscosity :25000~45000mPas; and Carbomer Homopolymer type C such as NM-Carbomer 970G, with 0.5% solution viscosity :40000~60000mPas; 

2) Carbomer Copolymer: Due to their unique chemical structure, as a pharmaceutical excipient t, they have good electrolyte tolerance. carbomer copolymer type A such as NM-Carbomer TR-2 P, with 1.0% solution viscosity: 4,500–13,500 mPas; and Carbomer copolymer type B such as NM-Carbomer TR-1P, with 1.0% solution viscosity:10,000–29,000 mPas; and carbomer Copolymer Type C such as NM-Carbomer 1382G, with 1.0% solution viscosity: 25,000–45,000 mPas.

3) Carbomer interpolymer: Carbomer interpolymer Type A, such as NM-Carbomer 10G, Carbomer interpolymer type B such as carbomer 2020 G. 

All these Carbomers as excipients meet the requirements of major pharmacopoeia such as Chinese Pharmacopoeia 2020, US Pharmacopoeia USP/NF, European Pharmacopoeia EP, British Pharmacopoeia BP and other relevant regulations. 

This high-standard audit fully recognizes Anhui Newman's manufacturing strength, quality control, R&D capability and product quality. The audit team confirmed compliant production, advanced technology and qualified products, verifying stable supply of high-grade medical carbomer. We will uphold strict medical quality standards, upgrade techniques and products, expand industrial cooperation, boost healthcare industry with premium domestic excipients and strengthen high-end supply chain.